Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | May 30, 2024 | June 03, 2024 |
| Immunovant, Inc.IMVT · Entity 3632 | Director · Chief Executive Officer | April 16, 2025 | April 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date May 30, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 2,783 |
Reported balance
After 2024-05-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-30 · Grant · Acquired 2,783 · Balance 2,783 F1: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
Immunovant, Inc.
Report date April 16, 2025 · Filed April 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,178,191 |
Reported balance
After 2025-04-16 transaction · row 1
1 source rowRow 1 · 2025-04-16 · Sale · Disposed 8,321 · Balance 1,178,191 F1: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 12, 2023, the holder was granted 243,832 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 15,240 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2022 Filed Apr 29, 2022 11:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,622 | $4.72 | $7,655.84 |
DisclosureSEC source: 0001764013-22-000041 · wf-form4_165123029015521.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 557,106 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,760 of these RSUs vested on April 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| March 24, 2022 Filed Apr 14, 2022 11:16 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 19,227 | $5.90 | $113,439.30 |
DisclosureSEC source: 0001764013-22-000035 · wf-form4_164993497408514.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,728 F1 · security: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 25% of these RSUs vested on March 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 15:49 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 125,158 | $7.25 | $907,395.50 |
DisclosureSEC source: 0001764013-22-000009 · wf-form4_164191616856320.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,955 F1 · security: On August 3, 2021, the holder was granted 570,613 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 4, 2021, of which 37.5% of these RSUs vested on January 1, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 19:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | Disposition to issuerStock Option (right to buy) · Derivative | 464,700 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000095 · wf-form4_163164954372889.xml · derivative · entry 4 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 464,700 shares Expires 2031-03-19 F2 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 19:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 464,700 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001764013-21-000095 · wf-form4_163164954372889.xml · derivative · entry 3 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,700 Underlying: Common Stock · 464,700 shares Expires 2031-03-19 F2 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 19:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | Disposition to issuerStock Option (right to buy) · Derivative | 430,700 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001764013-21-000095 · wf-form4_163164954372889.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 430,700 shares Expires 2030-05-14 F1 · derivative.exercise_date: 25% of the shares underlying the options vested on May 15, 2021, and the remainder vested or vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| September 11, 2021 Filed Sep 14, 2021 19:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 430,700 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001764013-21-000095 · wf-form4_163164954372889.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,700 Underlying: Common Stock · 430,700 shares Expires 2030-05-14 F1 · derivative.exercise_date: 25% of the shares underlying the options vested on May 15, 2021, and the remainder vested or vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 20:06 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 570,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000068 · wf-form4_162810753247468.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,113 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: 37.5% of the RSUs will vest on January 1, 2022 and the remainder of the RSUs will vest on August 3, 2023, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:45 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041467 · doc4.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 20:45 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 58,200 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001209191-21-041467 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 464,700 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000040 · wf-form4_161650359586006.xml · derivative · entry 2 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,700 Underlying: Common Stock · 464,700 shares Expires 2031-03-19 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 12:46 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 132,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000040 · wf-form4_161650359586006.xml · nonDerivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,500 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| May 20, 2020 Filed May 22, 2020 19:00 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 40,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-20-031658 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 15, 2020 Filed May 18, 2020 12:26 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 430,700 | $0.00 Strike: $19.01 | $0.00 |
DisclosureSEC source: 0001209191-20-029926 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,700 Underlying: Common Stock · 430,700 shares Expires 2030-05-14 F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:06 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 66,600 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001493152-20-003663 · ownership.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,600 Underlying: Common Stock · 66,600 shares Expires 2030-03-06 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Incentive Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Incentive Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:59 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 1,479,043 | Not disclosed Strike: $7.86 | Not disclosed |
DisclosureSEC source: 0001209191-19-061600 · doc4.xml · derivative · entry 1 Salzmann Peter · CIK 0001796309 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,043 Underlying: Common Stock · 1,479,043 shares Expires 2029-06-19 F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 3,024,219 shares of Immunovant Sciences Ltd. at exercise price of $3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC). F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.